All Posts By

VBI

VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

By | Press Releases, Sci-B-Vac®
Vaccination complete in 1,537 subjects in PROTECT Phase 3 study No vaccine-related adverse events have been observed to-date Top-line data expected mid-2019 VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced...
Read More

VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards

By | Cytomegalovirus ("CMV"), Glioblastoma ("GBM"), Press Releases, Sci-B-Vac®
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of three Scientific and Clinical Advisory Boards (SABs) consisting of leading experts in infectious disease and immuno-oncology research and vaccine...
Read More

VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients

By | Glioblastoma ("GBM"), Press Releases
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modification Intermediate-dose study arm: enrollment complete Initial immunologic data from low and intermediate-dose cohorts expected in the fourth quarter 2018 VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage...
Read More